Well differentiated papillary mesothelial tumor: a new name and new problems

A Churg, F Galateau-Salle - Modern Pathology, 2022 - nature.com
Well-differentiated papillary mesothelial tumor (WDPMT, formerly called well-differentiated
papillary mesothelioma) is a morphologically distinctive lesion composed of expansile …

Application of a neural network whole transcriptome–based pan-cancer method for diagnosis of primary and metastatic cancers

JK Grewal, B Tessier-Cloutier, M Jones… - JAMA network …, 2019 - jamanetwork.com
Importance A molecular diagnostic method that incorporates information about the
transcriptional status of all genes across multiple tissue types can strengthen confidence in …

A phase II window of opportunity study of neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 blockade for patients with malignant pleural mesothelioma

HS Lee, HJ Jang, M Ramineni, DY Wang… - Clinical Cancer …, 2023 - AACR
Purpose: We report the results of a phase II, randomized, window-of-opportunity trial of
neoadjuvant durvalumab versus durvalumab plus tremelimumab followed by surgery in …

[HTML][HTML] Spatially resolved, high-dimensional transcriptomics sorts out the evolution of biphasic malignant pleural mesothelioma: new paradigms for immunotherapy

F Torricelli, B Donati, F Reggiani, V Manicardi, S Piana… - Molecular Cancer, 2023 - Springer
Abstract Background Malignant Pleural Mesothelioma (MPM) is a dreadful disease escaping
the classical genetic model of cancer evolution and characterized by wide heterogeneity …

[HTML][HTML] Multi-site tumor sampling highlights molecular intra-tumor heterogeneity in malignant pleural mesothelioma

C Meiller, F Montagne, TZ Hirsch, S Caruso, J De Wolf… - Genome Medicine, 2021 - Springer
Background Malignant pleural mesothelioma (MPM) is a heterogeneous cancer. Better
knowledge of molecular and cellular intra-tumor heterogeneity throughout the thoracic cavity …

ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma

I Opitz, A Scherpereel, T Berghmans… - European journal of …, 2020 - academic.oup.com
Abstract The European Respiratory Society (ERS)/European Society of Thoracic Surgeons
(ESTS)/European Association for Cardio-Thoracic Surgery (EACTS)/European Society for …

[HTML][HTML] Medulloblastoma: molecular classification-based personal therapeutics

TC Archer, EL Mahoney, SL Pomeroy - Neurotherapeutics, 2017 - Elsevier
Recent advances in cancer genomics have revealed 4 distinct subgroups of
medulloblastomas, each with unique transcription profiles, DNA alterations and clinical …

[HTML][HTML] Emerging treatments for malignant pleural mesothelioma: where are we heading?

L Cantini, R Hassan, DH Sterman, JGJV Aerts - Frontiers in Oncology, 2020 - frontiersin.org
Malignant pleural mesothelioma (MPM) is an uncommon but aggressive and treatment
resistant neoplasm with low survival rates. In the last years we assisted to an exponential …

[HTML][HTML] New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the …

FG Salle, N Le Stang, AG Nicholson… - Journal of thoracic …, 2018 - Elsevier
Introduction The 2015 WHO classification of tumors categorized malignant mesothelioma
into epithelioid, biphasic (BMM), and sarcomatoid (SMM) for prognostic relevance and …

[HTML][HTML] Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X

NM Joseph, YY Chen, A Nasr, I Yeh, E Talevich… - Modern …, 2017 - nature.com
Malignant mesothelioma is a rare cancer that arises from the mesothelial cells that line the
pleural cavity and less commonly from the peritoneal lining of the abdomen and pelvis. Most …